Hungry biotechs make better partners for Big Pharma
Fierce Biotech
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
- Amarin
- Amgen
- AMR101
- Amylin
- Ariad
- Avanafil
- Bio-T-Gel
- Biogen Idec
- BioSante
- Bristol-Myers Squibb
- Bydureon
- Carfilzomib
- Cell Therapeutics
- Chelsea Therapeutics
- Corcept Therapeutics
- Corlux
- Curis
- Dapagliflozin
- Discovery Labs
- Elan
- Eliquis
- Ironwood
- Kalydeco
- Levadex
- linaclotide
- MAP Pharmaceuticals
- Merck
- Northera
- ONYX Pharmaceuticals
- Pfizer
- pixantrone
- Protalix BioTherapeutics
- Qnexa
- ridaforolimus
- Roche
- Surfaxin
- Teva Pharmaceuticals
- Tysabri
- Uplypso
- Vertex
- vismodegib
- Vivus
- Xgeva
Curis Earns $8 Million Milestone As NDA Accepted By FDA
Seeking Alpha
FDA gives priority to Roche skin cancer drug vismodegib
Pharma Times, UK
Roche preps vismodegib app after Ph2 skin cancer success
Fierce Biotech
10 promising late-stage cancer drugs
Fierce Biotech

